Granisetron HCl Tablets Rx
Generic Name and Formulations:
Granisetron HCl 1mg.
Various generic manufacturers
Indications for Granisetron HCl Tablets:
Prevention of nausea and vomiting associated with chemotherapy (including high-dose cisplatin), and with radiation (including total body irradiation and fractionated abdominal radiation).
Chemotherapy: give only on the days chemotherapy is given. 2mg up to 1 hour before chemotherapy; or, 1mg up to 1 hour before chemotherapy, then 1mg 12 hours after initial dose. Radiation: 2mg within 1 hour of radiation.
Use IV form.
Abdominal surgery. May mask progressive ileus and/or gastric distention. Pre-existing arrhythmias or cardiac conduction disorders. Cardiac disease, concomitant cardio-toxic chemotherapy or electrolyte abnormalities: increased risk of QT prolongation. Pregnancy (Cat.B). Nursing mothers.
Selective 5-HT3 receptor antagonist.
Caution with drugs that affect CYP450 or prolong the QT interval.
Headache, asthenia, diarrhea, constipation; QT prolongation.
Formerly known under the brand name Kytril.
Clinical Pain Advisor Articles
- History of Migraine May Be Associated With Higher Risk for Cochlear Disorders
- Radiofrequency Denervation Efficacious in Treating Thoracic Zygapophyseal Joint Pain
- Symptom Severity, Sensory Sensitivity May Indicate Pain Centralization in Chronic Overlapping Pain Conditions
- Prescribed Opioids Difficulties Scale Effective for Assessing Concerns of Patients With Chronic Pain
- Predictors of Opioid Overdose in High-Risk Users
- Consensus Guidelines for the Use of Intravenous Ketamine for Chronic Pain
- Pain Societies Issue Guidelines on Use of Ketamine for the Management of Acute Pain
- Labor Epidural Analgesia Linked to Reduced Likelihood of Successful Breastfeeding
- Novel Oral Treatment Safe, Effective for Migraine Headache Relief
- DFN-02 Nasal Spray Safe, Effective for Acute Treatment of Episodic Migraine
- Higher PainDETECT Scores, Neuropathic Pain Preoperatively May Increase Risk for Chronic Pain Post-TKR
- Terms Used for Addiction May Be Associated With Explicit, Implicit Bias
- Erenumab Reduces Monthly Migraine Days in Patients With Treatment-Resistant Migraine
- Government and Industry Lead the Way in Funding USPSTF Systematic Reviews
- Communication-Based Intervention Increases Goals-of-Care Discussions Between Physicians, Patients With Serious Illness